Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Chlorpheniramine Maleate BP 2mg, Pseudoephedrine HCl BP 10mg, Paracetamol BP 120mg, per 5ml

Clinical medicine profile

Chlorpheniramine Maleate BP 2mg, Pseudoephedrine HCl BP 10mg, Paracetamol BP 120mg, per 5ml

Non-opioid analgesic / antipyretic

POM
Evidence state Source-linked Review date not recorded
Route
ORAL / RECTAL / IV
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Severe active hepatic disease / acute liver failure.
  • Hypersensitivity.
  • Chronic heavy alcohol use — use reduced maximum daily dose or avoid.

Precautions

  • Warnings Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Directions adults and children 12 years of age and over: take 1 tablet every 4 to 6 hours, not to exceed 6 tablets (24 mg) in 24 hours, or as directed by a doctor children under 12 years of age: consult a doctor

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Generally safe; prolonged high dose rare associations — prefer careful use in advanced CKD.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

PRIMARY toxicity organ in overdose; therapeutic doses usually safe if daily limits respected.

03 Clinical use

Use, effects & interactions

Indications

  • Uses temporarily relieves these symptoms due to hay fever (allergic rhinitis) or other upper respiratory allergies: sneezing runny nose itching of the nose or throat itchy, watery eyes Clinical selection for Chlorpheniramine Maleate BP 2mg, Pseudoephedrine HCl BP 10mg, Paracetamol BP 120mg, per 5ml should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Non-opioid analgesic / antipyretic.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Rare at therapeutic doses.
  • Serious: acute liver failure in overdose, rare severe skin reactions (SJS/TEN/AGEP).
  • First-line for mild–moderate pain and fever.
  • Calculate total daily exposure from all sources.
  • In overdose: timed levels + NAC per protocol — do not wait for symptoms.
04 Pharmacology

Mechanism & disposition

Paracetamol inhibits central prostaglandin synthesis via effects on cyclo-oxygenase pathways (including COX-2 preferential central effects) and may engage serotonergic descending pathways.

Inhibit COX↓ ProstaglandinsAnalgesia / anti-inflammatory
Read complete mechanism

Paracetamol inhibits central prostaglandin synthesis via effects on cyclo-oxygenase pathways (including COX-2 preferential central effects) and may engage serotonergic descending pathways. Antipyretic effect via hypothalamic heat-regulating centre. Minimal peripheral anti-inflammatory action.

Onset

30–60 minutes oral

Duration

4–6 hours

Route

ORAL / RECTAL / IV

Metabolism

(glucuronidation/sulfation); toxic NAPQI pathway via CYP2E1 when pathways saturated or glutathione depleted.

Half-life

~2–3 h; prolonged in liver disease/overdose.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Analgesic/antipyretic of choice in pregnancy when needed; use lowest effective dose/shortest duration.

Lactation

Compatible with breastfeeding at standard doses.

06 Kenya market

Brands & loaded prices

From—
Median—
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; Professional class pharmacology (Non-opioid analgesic / antipyretic)
Last reviewedNot recorded
EvidenceSource-linked
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.